Amgen (AMGN) Projected to Announce Earnings on Tuesday

Amgen (NASDAQ:AMGN) is expected to issue its Q3 2026 results after the market closes on Tuesday, November 3rd. Analysts expect the company to announce earnings of $5.79 per share and revenue of $10.08 billion for the quarter. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. Interested persons are encouraged to explore the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Tuesday, November 3, 2026 at 4:30 PM ET.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Tuesday, August 4th. The medical research company reported $6.29 EPS for the quarter, beating analysts’ consensus estimates of $5.62 by $0.67. The firm had revenue of $10.05 billion for the quarter, compared to analyst estimates of $9.43 billion. Amgen had a net margin of 22.95% and a return on equity of 124.14%. The company’s revenue for the quarter was up 9.5% compared to the same quarter last year. During the same period in the previous year, the business earned $6.02 earnings per share. On average, analysts expect Amgen to post $22.96 EPS for the current fiscal year and $24.60 EPS for the next fiscal year.

Amgen Stock Up 1.2%

NASDAQ AMGN opened at $444.63 on Tuesday. The stock’s 50 day simple moving average is $417.26 and its 200 day simple moving average is $371.70. Amgen has a one year low of $288.00 and a one year high of $450.98. The firm has a market cap of $240.38 billion, a PE ratio of 27.63, a price-to-earnings-growth ratio of 3.21 and a beta of 0.41. The company has a debt-to-equity ratio of 4.44, a current ratio of 1.37 and a quick ratio of 1.13.

Amgen Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, September 11th. Stockholders of record on Friday, August 21st were paid a $2.52 dividend. The ex-dividend date was Friday, August 21st. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.3%. Amgen’s dividend payout ratio (DPR) is 62.65%.

Insider Buying and Selling

In other news, SVP Nancy A. Grygiel sold 2,970 shares of the business’s stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $402.16, for a total value of $1,194,415.20. Following the sale, the senior vice president owned 7,340 shares of the company’s stock, valued at $2,951,854.40. The trade was a 28.81% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, SVP Rachna Khosla sold 2,000 shares of the stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $412.57, for a total transaction of $825,140.00. Following the transaction, the senior vice president owned 6,404 shares of the company’s stock, valued at $2,642,098.28. The trade was a 23.80% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 6,222 shares of company stock worth $2,540,926. Insiders own 0.85% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on AMGN. Bank of America upped their price target on shares of Amgen from $312.00 to $317.00 and gave the stock an “underperform” rating in a research report on Wednesday, August 5th. BMO Capital Markets lowered their price objective on shares of Amgen from $450.00 to $415.00 and set a “market perform” rating for the company in a research report on Monday, October 12th. Mizuho boosted their target price on shares of Amgen from $303.00 to $352.00 and gave the stock a “neutral” rating in a research note on Tuesday, August 18th. Scotiabank upped their target price on shares of Amgen from $450.00 to $500.00 and gave the stock an “outperform” rating in a research report on Monday, September 28th. Finally, Jefferies Financial Group reissued a “hold” rating and issued a $410.00 price target on shares of Amgen in a report on Wednesday, September 23rd. One research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, sixteen have given a Hold rating and three have assigned a Sell rating to the company. Based on data from MarketBeat.com, Amgen currently has a consensus rating of “Hold” and a consensus target price of $389.71.

Amgen News Summary

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen and AstraZeneca reported that Imdelltra combined with Imfinzi reduced the risk of death by 58% in a Phase 3 study of patients with extensive-stage small-cell lung cancer. Median overall survival reached 21.1 months, strengthening the commercial and pipeline outlook for Imdelltra. Amgen, AstraZeneca Drug Combo Shows Promising Survival Results in Tough-To-Treat Lung Cancer
• Positive Sentiment: The strong lung-cancer results received significant attention at ESMO 2026, with coverage describing Amgen’s data as “unprecedented.” The readout could support future regulatory and market-share expectations for Imdelltra. ESMO ‘26: A cancer vaccine debate, Roche’s KRAS progress and Amgen’s ‘unprecedented’ data
• Positive Sentiment: Oppenheimer reiterated its Outperform rating, indicating continued confidence in Amgen’s growth prospects and clinical pipeline. Oppenheimer Reiterates Outperform Rating on Amgen

About Amgen

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research focuses on areas including oncology, cardiovascular disease, inflammation, bone health, nephrology and neuroscience.

The company’s products include biologic and specialty medicines such as Enbrel for inflammatory diseases, Prolia and Evenity for osteoporosis, Xgeva for skeletal-related complications, Repatha for cardiovascular risk reduction, Otezla for inflammatory conditions, Tezspire for severe asthma, Blincyto for certain blood cancers, and Lumakras for specific cancers.

Founded in 1980, Amgen is headquartered in Thousand Oaks, California.